{"filings":[{"id":2199356,"accession_number":"0001628280-26-055962","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2026-08-12T12:18:05+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Madrigal expands board to nine, appoints J&J R&D chief John C. Reed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board grew from 8 to 9 members; Reed elected Class II director, term to 2027 annual meeting.","Reed is EVP Innovative Medicine R&D at Johnson & Johnson, leading oncology, immunology, neuroscience research.","Compensation: $50k cash retainer, $10k for Science & Tech Committee, $675k equity grant (50% options, 50% RSUs).","Reed joins Science and Technology Committee; no material transactions disclosed under Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1949842,"accession_number":"0001628280-26-050775","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2026-07-30T11:03:02+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q2 Rezdiffra sales $364.3M (+71% YoY); net loss $57.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Rezdiffra net sales $364.3M, up 71% from $212.8M in Q2 2025; over 49,000 patients on therapy as of June 30, 2026.","Net loss $57.9M ($1.99/share) vs. $42.3M ($1.50/share) a year ago; includes $25M one-time business development expense.","Cash and marketable securities $838.9M as of June 30, 2026, down from $988.6M at Dec. 31, 2025.","Three new resmetirom patents issued, including one for F4c (well-compensated cirrhosis) with protection into 2042.","MGL-2086 (oral GLP-1) Phase 1 SAD trial initiated in June 2026 for Rezdiffra combination program in MASH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1111036,"accession_number":"0001104659-26-075130","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2026-06-17T20:06:04+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Madrigal shareholders approve 2026 equity plans; Dr. Taub transitions to consultant role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Stockholders approved 2026 Stock Plan and 2026 Employee Stock Purchase Plan at annual meeting.","Dr. Rebecca Taub to transition from employee to consultant effective July 1, 2026; annual fee $100,000.","Board adopted Nonqualified Deferred Compensation Plan effective Aug 1, 2026 for key management and non-employee directors.","All director nominees re-elected; say-on-pay approved with 97% of votes for.","PricewaterhouseCoopers ratified as auditor for FY2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91578,"accession_number":"0001628280-26-030896","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q1 Rezdiffra net sales $311.3M (+127% YoY); pipeline expanded with siRNA deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 Rezdiffra net sales $311.3M, up 127% YoY from $137.3M; over 42,250 patients on therapy, 2.5x vs Q1 2025.","Licensed ARO-PNPLA3 from Arrowhead; clinical-stage siRNA targeting PNPLA3 mutation in MASH (≈30% of F2/F3 patients).","Net loss $94.4M ($3.25/share) vs $73.2M ($2.61) prior year; includes $54.3M one-time upfront BD expenses.","Cash $817.9M at Mar 31 (down from $988.6M Dec 31); MGL-2086 Phase 1 on track for Q2 2026.","Operating expenses $404.1M (incl $34M stock comp) vs $216.6M; SG&A up due to commercial investment."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":311337000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91577,"accession_number":"0001628280-26-027956","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Madrigal reclassifies two directors to balance board classes ahead of 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Julian C. Baker reclassified from Class III to Class I, term expiring at 2026 Annual Meeting.","Daniel J. Brennan reclassified from Class II to Class I, effective April 22, 2026.","Reclassification aims to achieve more equal apportionment among three board classes.","Baker, Brennan, and James Daly nominated for re-election at June 17, 2026 meeting.","No changes to committee assignments as a result of the reclassification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101771,"accession_number":"0001628280-26-009476","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2026-02-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal reports Q4 Rezdiffra sales $321M, FY $958M; pipeline expands with siRNA and GLP-1 deals","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 Rezdiffra net sales $321.1M; full-year net sales $958.4M, vs $180.1M in 2024.","More than 36,250 patients on Rezdiffra as of year-end 2025.","Cash, equivalents and marketable securities $988.6M as of Dec. 31, 2025.","Licensed global rights to six pre-clinical siRNA programs and oral GLP-1 (MGL-2086) to combine with Rezdiffra.","Secured Orange Book listed Rezdiffra patent with protection into 2045; also closed $500M credit facility."],"consensus_eps_estimate":null,"consensus_eps_actual":-12.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":958403000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101770,"accession_number":"0001104659-26-008698","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Madrigal gains full control over Rezdiffra patent term extensions from Roche","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Madrigal gets exclusive right to manage all patent term extensions for Rezdiffra, including Roche-owned and joint patents.","Royalty reduction on Rezdiffra net sales is deferred until expiration of certain patent term extensions that have been or could be filed.","Amendment modifies the 2008 Research, Development, and Commercialization Agreement with Roche.","Madrigal also obtains full rights over joint patent rights and know-how without consent or accounting to Roche."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118095,"accession_number":"0001628280-25-056533","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Madrigal appoints Rita Thakkar as SVP and Chief Accounting Officer, effective Jan 12, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rita Thakkar joins as principal accounting officer; Mardi Dier remains CFO and principal financial officer.","Thakkar previously SVP Global Business Operations at Bristol Myers Squibb and Chief Audit Officer at BMS and Celgene.","Annual base salary of $450,000 with target bonus of 40% of salary; initial equity grant valued at $1,932,000.","Equity award composed of 70% time-based RSUs (4-year vest) and 30% stock options (graded vest over 4 years).","Severance agreement provides 12 months salary and bonus upon qualifying separation, with enhanced benefits on change of control."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118094,"accession_number":"0001628280-25-048525","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q3 2025 Rezdiffra sales $287.3M, annualizing >$1B; licenses oral GLP-1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Rezdiffra net sales $287.3M in Q3 2025 vs $62.2M YoY; >29,500 patients on therapy.","Operating expenses $401.2M (R&D $174M incl upfront for CSPC, SG&A $209.1M).","Cash $1.1B; licensed global rights to oral GLP-1 (MGL-2086) from CSPC; clinic entry H1 2026.","New Orange Book patent for Rezdiffra covering weight-threshold dosing into 2045.","Launched Rezdiffra in Germany after EC conditional approval in August 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-10.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":637320000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134542,"accession_number":"0001628280-25-037596","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q2 2025: Rezdiffra sales $212.8M, 23k patients; new patent to 2045; $500M credit","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 Rezdiffra net sales $212.8M (vs $14.6M prior year); >23,000 patients on therapy as of June 30, 2025.","New U.S. patent (No. 12,377,104) covers Rezdiffra weight-threshold dosing; expires Feb 4, 2045 (previously Sept 30, 2044).","Licensed global rights to oral GLP-1 candidate SYH2086 from CSPC Pharma; enters clinic H1 2026 for MASH combination.","Secured $500M senior secured credit facility with Blue Owl: $350M initial term loan, $150M delayed draw, plus up to $250M incremental.","Positive CHMP opinion for Rezdiffra in Europe; EC decision expected Aug 2025; would be first MASH therapy in EU."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":350052000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134541,"accession_number":"0001104659-25-071928","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Madrigal in-licenses oral GLP-1 SYH2086 from CSPC for up to $2B in milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment of $120M; potential milestone payments up to $2B plus royalties on net sales.","Madrigal plans to start clinical development for SYH2086 in first half of 2026; deal expected to close Q4 2025.","Aims to combine Rezdiffra (resmetirom) with oral GLP-1 for MASH, citing enhanced antifibrotic benefit with modest weight loss.","CSPC retains rights to develop other oral GLP-1 agonists in China subject to conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.82,"calibrated_materiality_score":0.82,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134540,"accession_number":"0001628280-25-035506","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["1.01","1.02","2.03","7.01","9.01"],"status":"ready","headline":"Madrigal enters $500M credit facility with Blue Owl; $350M funded to repay debt and fund MASH pipeline","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$350M initial term loan funded at close; $150M delayed draw available through Dec 2027.","$121.6M used to repay existing Hercules Capital loan ($115M principal + fees), terminating that agreement.","Interest at base rate + 3.75% or Term SOFR + 4.75% (with 1% SOFR floor); maturity July 2030.","Uncommitted $250M incremental facility available by mutual consent for strategic expansion.","Covenant requires minimum $100M unrestricted cash at all times; secured by substantially all assets."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151388,"accession_number":"0001628280-25-032358","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Madrigal annual meeting results: directors re-elected, say-on-pay approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Re-elected four Class III directors: Julian C. Baker, Raymond Cheong, Jacqualyn A. Fouse, Richard S. Levy — each with >17 million votes for.","Ratified appointment of PricewaterhouseCoopers as independent auditor for fiscal 2025 (20.2M for, 180K against).","Advisory say-on-pay approved (18.7M for) and frequency of one year adopted (18.9M for one-year)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151387,"accession_number":"0001628280-25-021314","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q1 2025 revenue $137.3M from Rezdiffra; 17,000+ patients on therapy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net Rezdiffra sales of $137.3M in Q1 2025 vs. $0 in prior-year period as first commercial quarter.","Operating expenses $216.6M (up 42% YoY) driven by SG&A for Rezdiffra launch; R&D fell to $44.2M.","Cash, equivalents, restricted cash and marketable securities $848.1M at March 31, 2025.","Appointed David Soergel, M.D. as CMO; Jacqualyn Fouse, Ph.D. to Board of Directors.","Two-year F4c cirrhosis data from MAESTRO-NAFLD-1 accepted as EASL late-breaker (May 7–10)."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":137250000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151386,"accession_number":"0001628280-25-018242","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-04-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Madrigal CMO/President of R&D Rebecca Taub steps down, becomes Senior Advisor through Dec 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Taub transitions from CMO and President of R&D to Senior Scientific and Medical Advisor effective April 21, 2025, through end of 2025.","She will continue to serve on Madrigal's Board of Directors.","Will receive base salary of $621,000 through Dec 31, 2025, and eligible for a 50% target bonus.","Entered a Severance and Change of Control Agreement with standard severance: 12-month salary continuation, equity acceleration, and health benefits.","No successor named; Taub will provide transition support and scientific guidance for MASH programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170277,"accession_number":"0001193125-25-051461","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Madrigal appoints Jackie Fouse to Board; Fred Craves to retire in July 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Fred Craves, Ph.D. resigns from Madrigal's Board effective July 1, 2025; no disagreement cited.","Board expanded to 10 members; Jacqualyn Fouse, Ph.D. elected to fill new vacancy on March 10, 2025.","Fouse to serve on Audit and Nominating & Governance Committees; receives annual cash retainer of $50,000 plus committee fees.","Fouse granted $600,000 equity award (50% options, 50% RSUs) vesting over two years; prorated annual director award also granted.","Fouse is former CEO of Agios Pharmaceuticals and current Chair of Agios Board; over 30 years healthcare experience."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170276,"accession_number":"0001193125-25-035787","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q4 2024 Rezdiffra sales $103.3M; new 2-year data shows benefit in F4c MASH cirrhosis","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 and FY 2024 Rezdiffra net sales $103.3M and $180.1M; no product sales in prior year.","Over 11,800 patients on Rezdiffra at year-end 2024; cash and marketable securities $931.3M.","Two-year open-label data in compensated MASH cirrhosis (F4c): mean 6.7 kPa liver stiffness reduction (VCTE), statistically significant vs baseline.","51% of F4c patients achieved ≥25% reduction in liver stiffness; safety profile consistent with prior trials.","MAESTRO-NASH OUTCOMES trial fully enrolled (data anticipated 2027); CHMP opinion expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-21.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":180133000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170275,"accession_number":"0001193125-25-004939","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal reports preliminary Rezdiffra Q4 2024 net sales $100M–$103M; over 11,800 patients on therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 2024 Rezdiffra net sales $100M–$103M, full-year $177M–$180M.","Year-end cash, equivalents and marketable securities ~$931M.","Over 11,800 patients on Rezdiffra as of December 31, 2024.","EMA decision on Rezdiffra MAA expected mid-2025; German launch targeted H2 2025.","MAESTRO-NASH OUTCOMES trial in compensated cirrhosis fully enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187286,"accession_number":"0001193125-24-248137","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal posts Q3 2024 Rezdiffra net sales of $62.2M; commercial coverage exceeds 80%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Third-quarter 2024 net sales of Rezdiffra $62.2M; no product revenue in prior year.","Cash, equivalents, and marketable securities $1.0B at Sep 30, 2024.","Operating expenses $178.5M vs $98.5M YoY; SG&A $107.6M driven by commercial launch.","Commercial coverage achieved for >80% of lives; <5% require biopsy for diagnosis.","Completed enrollment in MAESTRO-NASH OUTCOMES trial for compensated NASH cirrhosis; EMA decision mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-19.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":76813000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203788,"accession_number":"0001193125-24-195400","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal reports Q2 2024 net sales of $14.6M from Rezdiffra launch; cash $1.1B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Rezdiffra U.S. launch generated $14.6M net sales in Q2 2024; no product sales in prior-year period.","Coverage in place for >50% of commercial lives; <5% of covered lives require biopsy.","EMA decision on resmetirom MAA expected mid-2025; plans to directly commercialize in Europe.","Q2 operating expenses $177.2M vs $86.5M YoY; SG&A drove increase on launch activities.","Cash, equivalents and marketable securities $1.1B vs $634.1M at Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-14.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":14638000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220376,"accession_number":"0001193125-24-170634","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Madrigal shareholders approve 750K share increase to stock plan, extend to 2035","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to 2015 Stock Plan, increasing share reserve by 750,000 shares.","Plan extended through 2035; clawback policy and one-year minimum vesting requirement added.","All three Class II director nominees (Sibold, Taub, Craves) elected with over 95% support.","PricewaterhouseCoopers ratified as independent auditor for FY2024 with 99.4% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220375,"accession_number":"0001193125-24-133196","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["1.01","1.02","8.01","9.01"],"status":"ready","headline":"Madrigal announces up to $300M ATM equity offering program with TD Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered into Sales Agreement with TD Cowen to sell up to $300M of common stock via ATM.","Prior ATM program with Cowen terminated; had generated $225.1M from 1,333,594 shares.","Filed prospectus supplement registering up to 7,045,385 shares for selling stockholder; Madrigal receives no proceeds.","Sales may be made through TD Cowen as agent or principal; company not obligated to sell any shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220374,"accession_number":"0001193125-24-132559","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal posts Q1 net loss of ~$147.5M as Rezdiffra launch ramps up","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Rezdiffra received FDA accelerated approval on March 14, 2024; first shipments to patients began in April.","No Q1 revenue; operating expenses of $152.0M (up 94% YoY) due to commercial preparation and headcount.","Cash, cash equivalents and marketable securities of $1.1B after $690M gross proceeds from public offering.","Appointed Mardi C. Dier as CFO on February 28, 2024.","European MAA for resmetirom validated and under EMA review."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220373,"accession_number":"0001193125-24-084797","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Madrigal raises ~$86M from underwriters' option exercise; total offering ~$660M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriters exercised option to purchase 346,153 shares at $260.00 per share.","Option exercise closed on April 2, 2024; net proceeds of ~$86 million.","Aggregate net proceeds from the offering and option exercise expected ~$660 million.","Offering included 750,000 shares and pre-funded warrants for 1,557,692 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240026,"accession_number":"0001193125-24-072706","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Madrigal raises ~$574M in public offering for Rezdiffra launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 750,000 shares at $260/share and 1,557,692 pre-funded warrants at $259.9999 each.","Net proceeds estimated at ~$574M; underwriters have 30-day option for up to 346,153 additional shares.","Proceeds to fund commercial launch of Rezdiffra (resmetirom) in the U.S. and for general corporate purposes.","Closing expected March 21, 2024; lock-up agreements for directors and officers for 60 days.","Underwriters include Goldman Sachs, Jefferies, Cowen, Evercore, Piper Sandler."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240025,"accession_number":"0001193125-24-068170","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Madrigal receives FDA accelerated approval for Rezdiffra, first NASH therapy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA grants accelerated approval for Rezdiffra in NASH with F2-F3 fibrosis; first approved therapy for NASH.","Approval based on Phase 3 MAESTRO-NASH: improved fibrosis and NASH resolution at 52 weeks vs placebo.","Prescribing info does not require liver biopsy; weight-based dosing (80mg <100kg, 100mg >=100kg).","Rezdiffra expected available in US in April via specialty pharmacy; patient support programs.","Most common adverse reactions: diarrhea, nausea, pruritus, abdominal pain. Continued approval contingent on confirmatory outcomes data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240024,"accession_number":"0001193125-24-049136","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Madrigal names Mardi Dier as CFO; Alex Howarth transitions to advisor; GC Brian Lynch to depart by May 31","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mardi Dier appointed SVP & CFO effective March 11, 2024; previously CFO of Acelyrin (IPO), Ultragenyx, Portola.","Dier receives $550K base salary, 45% target bonus, and $6.7M equity grant (RSUs, options, PSUs) under 2023 Inducement Plan.","Outgoing CFO Alex Howarth remains Senior Advisor to May 31; separation includes 12-month salary, target bonus, equity acceleration, health benefits.","SVP & General Counsel Brian Lynch to depart by May 31; similar separation terms: 12-month salary, target bonus, equity acceleration, health benefits.","No disagreements with accounting policies or internal controls related to either departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240023,"accession_number":"0001193125-24-049116","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal reports Q4 2023 cash of $634M, appoints new CFO, resmetirom PDUFA March 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Mardi C. Dier as CFO; previously CFO at Portola, Ultragenyx, and Acelyrin.","Resmetirom PDUFA date March 14, 2024; company anticipates first NASH approval.","Cash and marketable securities $634.1M at Dec 31, 2023, up from $358.8M at Dec 31, 2022.","Operating expenses Q4 2023 $117.2M vs $85.3M YoY; full year $380.5M vs $293.6M.","G&A expenses Q4 2023 $46.5M vs $14.6M YoY due to commercial launch preparation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":240022,"accession_number":"0001193125-24-004269","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Madrigal posts corporate presentation; full content not visible in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Madrigal posted a corporate presentation to its website for investor communications on January 8, 2024.","The presentation describes resmetirom as an investigational therapy not yet approved by FDA.","No specific new data or financial updates were extracted from the provided exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257539,"accession_number":"0001193125-23-270884","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q3 operating expenses $98.5M; FDA Priority Review for resmetirom; $500M October financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA accepted NDA for resmetirom, granted Priority Review; PDUFA date March 14, 2024; no advisory committee planned.","Bill Sibold appointed CEO in Sep 2023; previously EVP at Sanofi, led Dupixent launch.","$500M public offering closed Oct 2023; net proceeds $472M for pre-launch activities.","Cash and securities $232.4M as of Sep 30, 2023, prior to October offering.","Q3 2023 operating expenses $98.5M ($71.0M R&D, $27.6M G&A); nine-month total $263.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":-14.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257538,"accession_number":"0001193125-23-249192","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Madrigal raises ~$472M in stock/warrant offering to fund resmetirom launch prep","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 1,248,098 shares at $151.69 and 2,048,098 pre-funded warrants at $151.6899 per warrant.","Estimated net proceeds ~$472M (excluding underwriter's option); closing expected Oct 3, 2023.","Proceeds for clinical/commercial activities for potential U.S. launch of resmetirom and general corporate purposes.","Underwriters have 30-day option to purchase up to 494,429 additional shares.","Directors and executive officers subject to 60-day lock-up without underwriter consent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274884,"accession_number":"0001193125-23-241315","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-09-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Madrigal CCO Remy Sukhija departs; receives 12-month severance, bonus, option acceleration","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Commercial Officer Remy Sukhija leaves to pursue other opportunities, effective immediately.","Separation includes 12 months base salary and 40% target bonus paid over 12 months.","Stock options for 28,500 shares accelerated, becoming exercisable immediately.","Medical benefit coverage continued for 12 months post-departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274883,"accession_number":"0001193125-23-235340","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-09-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Madrigal adopts 2023 Inducement Plan reserving 500,000 shares for new hires ahead of commercial launch","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted Inducement Plan on Sept 8, 2023, reserving 500,000 shares of common stock for equity grants.","Plan approved without stockholder approval per Nasdaq Listing Rule 5635(c)(4); only new employees eligible.","Plan supports expected substantial headcount increase as company prepares for commercial launch.","Administered by Compensation Committee; awards include options, RSUs, performance awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274882,"accession_number":"0001193125-23-234395","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Madrigal appoints Bill Sibold as President & CEO, effective Sept 8, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bill Sibold appointed President & CEO effective Sept 8, 2023; also joins Board as Class II director.","Sibold compensation: $875k base salary, 75% target bonus, $520k sign-on cash, 50k time-based RSUs, 50k performance PSUs.","Former CEO Paul Friedman steps down but remains on Board; receives 12 months base salary plus 100% of target bonus.","Sibold previously EVP Specialty Care at Sanofi; prior roles at Biogen, Avanir. Yale BA, Harvard MBA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274881,"accession_number":"0001193125-23-234385","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-09-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Madrigal's NDA for resmetirom for NASH with fibrosis, grants Priority Review","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["PDUFA target action date set for March 14, 2024; FDA not currently planning an advisory committee meeting.","Priority Review shortens review to 6 months vs standard 10 months for a serious condition.","NDA supported by positive Phase 3 MAESTRO-NASH biopsy endpoints and large safety database from 18 studies.","Resmetirom is a once-daily oral THR-β agonist targeting key underlying causes of NASH in the liver."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274880,"accession_number":"0001193125-23-205600","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal submits resmetirom NDA for NASH; cash $298.4M as of June 30","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Resmetirom NDA submitted to FDA for accelerated approval of NASH with liver fibrosis.","Cash, cash equivalents and marketable securities $298.4M at June 30, 2023, down from $358.8M at Dec 31, 2022.","Operating expenses for six months ended June 30, 2023: $164.8M (R&D $130.8M, G&A $34.0M), up from $127.9M in prior year.","Interest income $7.3M and interest expense $5.2M for six months; cash used in operations $159.4M.","ICER final report indicates resmetirom may be cost-effective for at-risk NASH; disease education campaigns launched."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274879,"accession_number":"0001193125-23-187698","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Madrigal completes NDA submission to FDA for resmetirom for NASH with liver fibrosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Completed rolling NDA submission to FDA for resmetirom for NASH with liver fibrosis; priority review requested.","Phase 3 MAESTRO-NASH met both primary liver biopsy endpoints: NASH resolution and fibrosis reduction.","Resmetirom granted Breakthrough Therapy designation by FDA in April 2023.","Two ongoing Phase 3 outcomes studies (MAESTRO-NASH-OUTCOMES, MAESTRO-NAFLD-OLE) to support full approval.","No approved therapy exists for NASH; resmetirom targets key underlying causes as THR-β agonist."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292240,"accession_number":"0001193125-23-179440","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Madrigal initiates rolling NDA for resmetirom in NASH with liver fibrosis","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Initiated rolling NDA submission to FDA seeking accelerated approval for resmetirom for NASH with liver fibrosis.","Expects to complete full NDA submission in July 2023; will request priority review.","Resmetirom granted Breakthrough Therapy designation in April 2023 for NASH with liver fibrosis.","NDA based on MAESTRO-NASH biopsy trial meeting both histological improvement endpoints proposed by FDA.","Resmetirom has potential to become first approved therapy for NASH with liver fibrosis if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292239,"accession_number":"0001193125-23-169190","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Madrigal appoints Julian Baker as Chairman, adds two Baker Bros. affiliates to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keith Gollust and David Milligan resigned as Class III directors effective June 15, 2023; no disagreement cited.","Julian Baker appointed independent Chairman; Raymond Cheong also appointed as Class III director.","Both new directors are affiliated with Baker Bros. Advisors LP, a significant shareholder.","Baker Bros. waived director nomination rights under Securities Purchase Agreement while Baker or Cheong serve.","CEO Paul Friedman remains; Chairman and CEO roles separated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292238,"accession_number":"0001193125-23-169187","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-06-20T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Madrigal stockholders approve charter amendment for officer exculpation at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All three Class I director nominees elected: Paul Friedman, Kenneth Bate, James Daly.","Ratification of PwC as independent auditor for FY2023 approved (16,111,585 for, 12,542 against).","Advisory vote on executive compensation passed with 93.56% of votes cast FOR.","Amendment to certificate of incorporation to provide officer exculpation from breach of fiduciary duty of care approved and filed June 16, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292237,"accession_number":"0001193125-23-138953","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Madrigal ups ATM equity facility by $200M to raise additional capital via Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to Sales Agreement with Cowen increases ATM capacity by $200M.","Shares sold through 'at-the-market' offerings under existing shelf registration.","Company has no obligation to sell; Cowen acts as agent on commercially reasonable efforts.","Prospectus supplement filed May 9, 2023 for the additional $200M of common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":292236,"accession_number":"0001193125-23-138931","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q1 cash burn $84.1M; resmetirom NDA on track for Q2 2023 with Breakthrough Therapy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and securities $329.5M at March 31, 2023, down from $358.8M at Dec 31, 2022.","Operating expenses $78.3M for Q1 2023, up from $57.6M in Q1 2022; R&D $62.2M, G&A $16.2M.","Resmetirom NDA for NASH with fibrosis remains on track for Q2 2023; FDA Breakthrough Therapy designation received.","MAESTRO-NASH trial enrollment complete; primary results to be presented at EASL in June 2023.","Interest income rose to $3.8M from $0.1M; interest expense $2.3M from loan facility."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312950,"accession_number":"0001193125-23-045671","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal reports Q4 2022 cash $358.8M; positive Phase 3 NASH results support H1 2023 NDA filing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities $358.8M at Dec 31, 2022, up from $270.3M at Dec 31, 2021.","Operating expenses $85.3M (Q4) and $293.6M (FY2022), vs $64.6M and $242.5M in prior year periods.","R&D expenses $70.7M (Q4) and $245.4M (FY2022), increases due to Phase 3 trials and headcount.","Positive Phase 3 MAESTRO-NASH results achieved both primary endpoints; NDA filing for resmetirom planned H1 2023.","Secured $250M term loan facility with Hercules Capital and $300M+ in financing events in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-17.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312949,"accession_number":"0001193125-23-030281","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Madrigal amends credit agreement: rate cut 150bps, extra $15M tranche, $35M draw","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Borrowing cost reduced ~150bps to 10.2% as of Feb 3, 2023; interest-only now through May 1, 2025.","Tranche 2 increased by $15M to $65M; $35M drawn immediately, up to $30M more available in two $15M tranches.","Tranche 4 reduced by $15M to $60M (discretionary); total facility remains $250M, $85M now outstanding.","Unvested warrants for 59,545 shares canceled; new warrants issued for 2,543 shares at $285.31 per share.","Additional $15M Tranche 2 draw available by June 19, 2023; another $15M by Sep 30, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":312948,"accession_number":"0001193125-23-005674","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Madrigal reports supportive MAESTRO-NASH consensus read; NASH resolution and fibrosis improvement remain significant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Consensus read: NASH resolution 24% (80mg) and 28% (100mg) vs 8% placebo (p<0.0001).","Fibrosis improvement ≥1 stage: 24% (80mg) and 26% (100mg) vs 12% placebo (p<0.0001).","Analysis used digitized biopsies when two pathologists' scores disagreed on primary endpoints.","Results consistent with primary analysis announced Dec 19, 2022; trial continues for up to 54 months.","Data presented at NASH-TAG Conference on Jan 6, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331474,"accession_number":"0001193125-22-311537","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2022-12-23T23:59:59+00:00","items":["1.01","5.03","7.01","8.01","9.01"],"status":"ready","headline":"Madrigal raises $259M in equity and $50M debt capacity; NDA submission planned H1 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$159M in gross ATM common stock sales and $100M registered direct offering (Series B preferred and common) completed.","Hercules Capital confirms clinical milestone, enabling $50M additional draw under existing credit facility.","Net proceeds ~$305.4M to fund resmetirom development and potential U.S. launch.","Company intends to submit new drug application for resmetirom in first half of 2023.","Series B preferred convertible at $225/share, substantially similar to existing Series A; closing expected Dec 23, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331473,"accession_number":"0001193125-22-307935","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["7.01","8.01"],"status":"ready","headline":"Madrigal Phase 3 MAESTRO-NASH meets dual primary endpoints; NDA planned H1 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NASH resolution endpoint met: 30% on 100mg vs 10% placebo (p<0.0001); fibrosis improvement: 26% vs 14% (p=0.0002).","LDL-C lowering at 24 weeks: -16% on 100mg vs -1% placebo (p<0.0001); both doses statistically significant.","Safety similar across arms: SAEs 11.8-12.7%; discontinuation low (2.8-7.7%); common AEs mild diarrhea and nausea.","Company plans to file NDA for accelerated approval (Subpart H) in first half of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":331472,"accession_number":"0001193125-22-276424","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal Q3 cash $153.2M; MAESTRO-NASH topline data on track for Q4 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents and marketable securities $153.2M at Sep 30, 2022, down from $270.3M at Dec 31, 2021.","R&D expenses $68.3M for Q3 2022 vs $54.9M in Q3 2021; G&A $12.1M vs $8.3M.","Cash used in operations for nine months ended Sep 30, 2022 was $166.3M.","Topline data from Phase 3 MAESTRO-NASH biopsy study expected in Q4 2022; NDA filing planned H1 2023.","Two resmetirom oral abstracts accepted at AASLD Liver Meeting presenting cirrhosis and noninvasive data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":348997,"accession_number":"0001193125-22-211760","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Madrigal on track for MAESTRO-NASH topline data in Q4 2022; Q2 cash $211.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Topline data from Phase 3 MAESTRO-NASH biopsy study expected in Q4 2022; NDA filing planned for H1 2023.","Cash, cash equivalents and marketable securities of $211.8M as of June 30, 2022, down from $270.3M at Dec 31, 2021.","Q2 2022 operating expenses $70.3M (R&D $58.5M, G&A $11.8M) vs $61.7M in Q2 2021.","Expanded market development activities; payer education sessions covering >80% of U.S. branded prescriptions.","Plans to initiate MAESTRO-NASH Outcomes study in ~700 early NASH cirrhosis patients for full approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":365819,"accession_number":"0001193125-22-176256","cik":1157601,"company_name":"MADRIGAL PHARMACEUTICALS, INC.","ticker":"MDGL","form_type":"8-K","filed_at":"2022-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Madrigal shareholders elect three Class III directors, ratify PwC, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class III directors elected: Gollust 9.6M for/2.2M withheld, Levy 10.5M/1.3M, Milligan 11.6M/116K.","Ratification of PricewaterhouseCoopers as auditor: 14.7M for, 19.8K against, 51K abstain.","Advisory vote on executive compensation: 11.6M for, 111.9K against (99.0% of votes cast).","Quorum of 14.78M shares present out of 17.10M outstanding as of April 27, 2022 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12171081643.246347,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-17T23:59:59+00:00|365819"}